Assembly Biosciences

Assembly Biosciences EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of Assembly Biosciences (ASMB) as of Nov 5, 2026 is -4.70 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was -38.11 % — a change of -87.66% (higher).

EBIT/Assets

-4.70 %

YoY

-87.66%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of Assembly Biosciences is 2025 -4.70 % . Operating Income to Assets Ratio (EBIT/Assets) of Assembly Biosciences was 2024 -38.11 % . It decreases by -87.66% higher compared to the previous year.

The Assembly Biosciences EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2018
-34.60 USD
Jan 1, 2019
-29.52 USD
Jan 1, 2020
-22.87 USD
Jan 1, 2021
-69.45 USD
Jan 1, 2022
-92.46 USD
Jan 1, 2023
-47.25 USD
Jan 1, 2024
-38.11 USD
Jan 1, 2025
-4.70 USD
The Assembly Biosciences EBIT/Assets history
YEAREBIT/AssetsYoY
-4.70 %-87.66%
-38.11 %-19.33%
-47.25 %-48.90%
-92.46 %+33.13%
-69.45 %+203.69%
-22.87 %-22.54%
-29.52 %-14.66%
-34.60 %+12.15%
-30.85 %-33.15%
-46.15 %+108.12%
-22.17 %-34.08%
-33.63 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Assembly Biosciences Stock analysis

What does Assembly Biosciences do? Assembly Biosciences develops oral therapeutics for hepatitis B virus (HBV) infection through its CpAM platform, targeting the HBV core protein with small molecules. The company also focuses on microbiome restoration using GEMICEL, an oral delivery system for live biologic therapies targeting the lower gastrointestinal tract. Its lead product candidate is in development for chronic hepatitis B virus and dysbiotic microbiome conditions. The company's primary products include CpAMs for HBV treatment and GEMICEL-based microbiome therapeutics, designed for patients with chronic HBV and microbiome-related illnesses. These products are developed for medical use in infectious disease management, targeting healthcare providers and pharmaceutical partners seeking novel therapeutic solutions. Assembly Biosciences' revenue streams are derived from the development and potential future commercialization of its HBV and microbiome platform programs, with no current indication of licensing or partnership agreements mentioned in the business description. Assembly Biosciences is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Assembly Biosciences stock

Operating Income to Assets Ratio (EBIT/Assets) of Assembly Biosciences is -4.70 % in 2025.

Operating Income to Assets Ratio (EBIT/Assets) of Assembly Biosciences changed from -38.11 % to -4.70 %, representing a -87.66% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) Assembly Biosciences since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s Assembly Biosciences with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Assembly Biosciences

All Key Metrics — Assembly Biosciences